1. 1590 Patient-related factors in determining the emetic risk potential for patients undergoing chemotherapy: An evaluation of predictive models for the development of a risk assessment tool. (September 2015) Authors: Aapro, M.; Dielenseger, P.; Dranitsaris, G.; Jordan, K.; Molassiotis, A.; Roeland, E.; Schwartzberg, L.; Warr, D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting. (December 2020) Authors: Clemons, M.; Dranitsaris, G.; Sienkiewicz, M.; Sehdev, S.; Ng, T.; Robinson, A.; Mates, M.; Hsu, T.; McGee, S.; Freedman, O.; Kumar, V.; Fergusson, D.; Hutton, B.; Vandermeer, L.; Hilton, J. Journal: Breast Issue: Volume 54(2020) Page Start: 278 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. What is a new drug worth? An innovative model for performance‐based pricing. (25th September 2014) Authors: Dranitsaris, G.; Dorward, K.; Owens, R.C.; Schipper, H. Journal: European journal of cancer care Issue: Volume 24:Number 3(2015:May) Page Start: 313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗